Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like Short-term, self-regulating therapies may help alleviate long COVID symptoms March 13, 2024 Transforming the narrative on ultraprocessed foods by mirroring anti-tobacco strategies May 28, 2025 Healthy fats from fish and nuts may slow lung scarring, delay transplants January 2, 2024